New diabetes clinical trial: An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Published on: June 17, 2019 at 07:00PM
Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: Faster-acting insulin aspart
Sponsor:   Novo Nordisk A/S
Not yet recruiting